MedTrace Logo

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

NCT05904457 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-06-15

No results posted yet for this study

Summary

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle

Conditions

Interventions

DRUG

bevacizumab

Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.

DRUG

erlotinib

Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Korean Cancer Study Group

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2025-01-31
Completion
2026-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904457 on ClinicalTrials.gov